<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01229397</url>
  </required_header>
  <id_info>
    <org_study_id>INF-V-A005</org_study_id>
    <nct_id>NCT01229397</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of a Single 0.5 mL Dose of Inflexal V With a 0.25 mL 2-dose Regimen of Inflexal V</brief_title>
  <official_title>A Phase III Open, Randomized, Parallel, Multi-center Study in Children Aged 6 - 35 Months to Compare the Immunogenicity and Safety of a Single 0.5 mL Dose of Inflexal V With a 0.25 mL 2-dose Regimen of Inflexal V Administered According to a 0/4 Week Schedule</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Crucell Holland BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Crucell Holland BV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to evaluate the immunogenicity of a single full (0.5 mL) dose and a 0.25 mL
      2-dose regime of Inflexal V in unprimed children aged 6 - &lt;36 months, using the EMA guideline
      for the re-registration of the seasonal influenza vaccine in adults (aged ≥18 ≤60 years) as
      reference.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity of a Single Full (0.5 mL) Dose and a 0.25 mL 2-dose Regimen of Inflexal V, Using the EMA Guideline for the Re-registration of the Seasonal Influenza Vaccine in Adults (Aged ≥18 to ≤60 Years) as Reference</measure>
    <time_frame>This assesment was done for immunogenicity data collected at Day 29 after completion of designated vaccination regimen</time_frame>
    <description>Seroprotection rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity of a Single Full (0.5 mL) Dose and a 0.25 mL 2-dose Regimen of Inflexal V, Using the EMA Guideline for the Re-registration of the Seasonal Influenza Vaccine in Adults (Aged ≥18 to ≤60 Years) as Reference</measure>
    <time_frame>This assesment was done for immunogenicity data collected at Day 29 after completion of designated vaccination regimen</time_frame>
    <description>Seroconversion rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity of a Single Full (0.5 mL) Dose and a 0.25 mL 2-dose Regimen of Inflexal V, Using the EMA Guideline for the Re-registration of the Seasonal Influenza Vaccine in Adults (Aged ≥18 to ≤60 Years) as Reference</measure>
    <time_frame>This assesment was done for immunogenicity data collected at Day 29 after completion of designated vaccination regimen</time_frame>
    <description>GMT-fold increase - calculated as the GMT on Day 22 divided by the baseline GMT value</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Local and Systemic Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Solicited local and systemic AEs were collected from Day 1 (day of vaccination) to Day 4 inclusive using a subject diary</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">205</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Inflexal V 0.25 mL x 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Inflexal V 0.5 mL x 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inflexal V</intervention_name>
    <description>vaccination with Inflexal V 0.25 mL administered twice, 4 weeks apart</description>
    <arm_group_label>Inflexal V 0.25 mL x 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inflexal V</intervention_name>
    <description>Inflexal V 0.5 mL administrated once only</description>
    <arm_group_label>Inflexal V 0.5 mL x 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female children

          -  Aged ≥6 to &lt;36 months on Day 1

          -  Born at a gestational age ≥37 weeks

          -  Written informed consent

          -  No previous influenza vaccination

        Exclusion Criteria:

          -  Acute respiratory infection or other acute disease

          -  Acute febrile illness (≥38.0 °C)

          -  Past vaccination with an influenza vaccine, including vaccination against the
             influenza strain A/California/7/2009 (H1N1)-like virus

          -  Laboratory-confirmed infection with any influenza strain, including the pandemic
             influenza strain H1N1 (A/California/7/2009 (H1N1)-like virus)

          -  Known hypersensitivity to any vaccine component

          -  Known history of egg protein allergy or severe atopy

          -  Known blood coagulation disorder

          -  Chronic (longer than 14 days) administration of immunosuppressants or other
             immune-modifying drugs within 6 months before the first dose of the study vaccine,
             incl. oral corticosteroids in dosages of ≥0.5 mg/kg/d prednisolone or equivalent for
             ≥14 days (inhaled or topical steroids are allowed)

          -  Known immunodeficiency (including leukemia, cancer, HIV seropositivity)

          -  Investigational medicinal product received in the past 3 months (90 days)

          -  Treatment with immunoglobulins or blood transfusion(s) received in the past 3 months
             (90 days)

          -  Vaccination with the MMR vaccine in the past 4 weeks, or planned within the study
             period

          -  Participation in another clinical trial

          -  Child or legal charge of the investigator or an employee at the study site, or living
             in the same household as the investigator/employee and/or dependent on the
             investigator/employee

          -  Suspected non-compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>35 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicola Principi, Prof Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Paediatrics, University of Milan, Fondazione IRCCS &quot;Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena&quot;, Via Commenda 9, 20122, Milano, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gian Vincenzo Zuccotti, Prof Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pediatrics, Department of Clinical Sciences, Università di Milano, L. Sacco Hospital, 74, Via GB Grassi,</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Paediatrics, University of Milan, Fondazione IRCCS &quot;Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena&quot;</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pediatrics, Department of Clinical Sciences, Università di Milano, L. Sacco Hospital</name>
      <address>
        <city>Milan</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2010</study_first_submitted>
  <study_first_submitted_qc>October 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2010</study_first_posted>
  <results_first_submitted>October 23, 2012</results_first_submitted>
  <results_first_submitted_qc>March 20, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 20, 2013</results_first_posted>
  <last_update_submitted>January 7, 2014</last_update_submitted>
  <last_update_submitted_qc>January 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Virus</keyword>
  <keyword>Vaccination</keyword>
  <keyword>Immunisation</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: 05 October - 17 January 2011; Location: University of Milan</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Inflexal V 0.25 mL x 2</title>
          <description>2 doses of Inflexal V influenza vaccine (surface antigen, inactivated, virosome) 2010/2011, 4 weeks apart, containing per 0.25 mL dose:
7.5 μg HA antigen of A/California/7/2009 (H1N1)-like virus
7.5 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus
7.5 μg HA antigen of B/Brisbane/60/2008-like virus</description>
        </group>
        <group group_id="P2">
          <title>Inflexal V 0.5 mL x 1</title>
          <description>1 dose of Inflexal V influenza vaccine (surface antigen, inactivated, virosome) 2010/2011, containing per 0.5 mL dose:
15 μg HA antigen of A/California/7/2009 (H1N1)-like virus
15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus
15 μg HA antigen of B/Brisbane/60/2008-like virus</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Migrated/moved from study area</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Inflexal V 0.25 mL x 2</title>
          <description>Two 0.25 mL doses (on Day 1 and 29)</description>
        </group>
        <group group_id="B2">
          <title>Inflexal V 0.5 mL x 1</title>
          <description>One 0.5 mL dose (on Day 1)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="103"/>
            <count group_id="B2" value="102"/>
            <count group_id="B3" value="205"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.8" spread="0.52"/>
                    <measurement group_id="B2" value="1.8" spread="0.61"/>
                    <measurement group_id="B3" value="1.8" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Immunogenicity of a Single Full (0.5 mL) Dose and a 0.25 mL 2-dose Regimen of Inflexal V, Using the EMA Guideline for the Re-registration of the Seasonal Influenza Vaccine in Adults (Aged ≥18 to ≤60 Years) as Reference</title>
        <description>Seroprotection rate</description>
        <time_frame>This assesment was done for immunogenicity data collected at Day 29 after completion of designated vaccination regimen</time_frame>
        <population>Intention to treat population, vaccinated subjects with available pre- and post-vaccination titers</population>
        <group_list>
          <group group_id="O1">
            <title>Inflexal V 0.25 mL x 2</title>
            <description>Two 0.25 mL doses (on Day 1 and 29)</description>
          </group>
          <group group_id="O2">
            <title>Inflexal V 0.5 mL x 1</title>
            <description>One 0.5 mL dose (on Day 1)</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity of a Single Full (0.5 mL) Dose and a 0.25 mL 2-dose Regimen of Inflexal V, Using the EMA Guideline for the Re-registration of the Seasonal Influenza Vaccine in Adults (Aged ≥18 to ≤60 Years) as Reference</title>
          <description>Seroprotection rate</description>
          <population>Intention to treat population, vaccinated subjects with available pre- and post-vaccination titers</population>
          <units>percentage subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage of subjects seroprotected: A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.0" lower_limit="94.4" upper_limit="100"/>
                    <measurement group_id="O2" value="98.0" lower_limit="92.9" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of subjects seroprotected: A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.0" lower_limit="94.4" upper_limit="100"/>
                    <measurement group_id="O2" value="97.0" lower_limit="91.4" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of subjects seroprotected: B-strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.2" lower_limit="85.8" upper_limit="97.1"/>
                    <measurement group_id="O2" value="86.9" lower_limit="78.6" upper_limit="92.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Local and Systemic Adverse Events as a Measure of Safety and Tolerability</title>
        <time_frame>Solicited local and systemic AEs were collected from Day 1 (day of vaccination) to Day 4 inclusive using a subject diary</time_frame>
        <population>Safety population, all vaccinated subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Inflexal V 0.25 mL x 2 - After 1st Vaccination</title>
          </group>
          <group group_id="O2">
            <title>Inflexal V 0.25 mL x 2 - After 2nd Vaccination</title>
          </group>
          <group group_id="O3">
            <title>Inflexal V 0.5 mL x 1</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Local and Systemic Adverse Events as a Measure of Safety and Tolerability</title>
          <population>Safety population, all vaccinated subjects</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs (unsolicited and solicited)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unsolicited AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Solicited local AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Solicited systemic AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Immunogenicity of a Single Full (0.5 mL) Dose and a 0.25 mL 2-dose Regimen of Inflexal V, Using the EMA Guideline for the Re-registration of the Seasonal Influenza Vaccine in Adults (Aged ≥18 to ≤60 Years) as Reference</title>
        <description>Seroconversion rate</description>
        <time_frame>This assesment was done for immunogenicity data collected at Day 29 after completion of designated vaccination regimen</time_frame>
        <population>Intention to treat population, vaccinated subjects with available pre- and post-vaccination titers</population>
        <group_list>
          <group group_id="O1">
            <title>Inflexal V 0.25 mL x 2</title>
            <description>Two 0.25 mL doses (on Day 1 and 29)</description>
          </group>
          <group group_id="O2">
            <title>Inflexal V 0.5 mL x 1</title>
            <description>One 0.5 mL dose (on Day 1)</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity of a Single Full (0.5 mL) Dose and a 0.25 mL 2-dose Regimen of Inflexal V, Using the EMA Guideline for the Re-registration of the Seasonal Influenza Vaccine in Adults (Aged ≥18 to ≤60 Years) as Reference</title>
          <description>Seroconversion rate</description>
          <population>Intention to treat population, vaccinated subjects with available pre- and post-vaccination titers</population>
          <units>percentage subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage of subjects seroconverted: A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.9" lower_limit="85.1" upper_limit="97.3"/>
                    <measurement group_id="O2" value="95.5" lower_limit="88.8" upper_limit="98.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of subjects seroconverted: A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.0" lower_limit="94.4" upper_limit="100"/>
                    <measurement group_id="O2" value="97.0" lower_limit="91.4" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of subjects seroconverted: B-strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.9" lower_limit="85.8" upper_limit="97.1"/>
                    <measurement group_id="O2" value="86.9" lower_limit="78.6" upper_limit="92.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Immunogenicity of a Single Full (0.5 mL) Dose and a 0.25 mL 2-dose Regimen of Inflexal V, Using the EMA Guideline for the Re-registration of the Seasonal Influenza Vaccine in Adults (Aged ≥18 to ≤60 Years) as Reference</title>
        <description>GMT-fold increase - calculated as the GMT on Day 22 divided by the baseline GMT value</description>
        <time_frame>This assesment was done for immunogenicity data collected at Day 29 after completion of designated vaccination regimen</time_frame>
        <population>Intention to treat population, vaccinated subjects with available pre- and post-vaccination titers</population>
        <group_list>
          <group group_id="O1">
            <title>Inflexal V 0.25 mL x 2</title>
            <description>Two 0.25 mL doses (on Day 1 and 29)</description>
          </group>
          <group group_id="O2">
            <title>Inflexal V 0.5 mL x 1</title>
            <description>One 0.5 mL dose (on Day 1)</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity of a Single Full (0.5 mL) Dose and a 0.25 mL 2-dose Regimen of Inflexal V, Using the EMA Guideline for the Re-registration of the Seasonal Influenza Vaccine in Adults (Aged ≥18 to ≤60 Years) as Reference</title>
          <description>GMT-fold increase - calculated as the GMT on Day 22 divided by the baseline GMT value</description>
          <population>Intention to treat population, vaccinated subjects with available pre- and post-vaccination titers</population>
          <units>Fold (ratio)</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GMT fold increase from baseline: A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.5" lower_limit="21.3" upper_limit="30.5"/>
                    <measurement group_id="O2" value="19.6" lower_limit="16.9" upper_limit="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT fold increase from baseline: A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.6" lower_limit="26.7" upper_limit="37.3"/>
                    <measurement group_id="O2" value="24.6" lower_limit="20.7" upper_limit="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT fold increase from baseline: B-strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" lower_limit="11.2" upper_limit="14.6"/>
                    <measurement group_id="O2" value="14.7" lower_limit="12.3" upper_limit="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Any AE occurring within 1 month (minimum 28 days) following vaccine administration was recorded. Any SAE occurring from study start up to 6 months (at least 180 days) following vaccine administration was recorded.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Inflexal V 0.25 mL x 2 - After 1st Vaccination</title>
        </group>
        <group group_id="E2">
          <title>Inflexal V 0.25 mL x 2 - After 2nd Vaccination</title>
        </group>
        <group group_id="E3">
          <title>Inflexal V 0.5 mL x 1</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Gastroenterisits rotavirus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="102"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="101"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="102"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="101"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Erythema (at the injection site)</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="102"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="101"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Induration (at the injection site)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="102"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="101"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Pain (at the injection site)</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="102"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="101"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Haemorrhage (at the injection site)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="101"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="102"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="101"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="101"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="101"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="101"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is at least 60 days from the time submitted to the sponsor for review. The sponsor reserves the right to remove any proprietary or confidential information and to require that publication be delayed for up to 60 additional days to enable the sponsor to prepare and file patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Affairs Director</name_or_title>
      <organization>Crucell Switzerland AG</organization>
      <phone>+41(0)319806111</phone>
      <email>info@crucell.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

